Are Lloyds Banking Group PLC And GlaxoSmithKline plc Bargain Buys For 2016?

Why Lloyds Banking Group PLC (LON:LLOY) and GlaxoSmithKline plc (LON:GSK) could reverse recent losses and beat the market in 2016.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Lloyds Banking Group (LSE: LLOY) and GlaxoSmithKline (LSE: GSK) may beat the FTSE 100 this year, but both stocks look likely to end the year lower than they started. Will they bounce back next year?

GlaxoSmithKline: On the rise

Shares in Glaxo are now down by nearly 25% from the highs seen in 2013. In fairness, this weakness has been justified by the firm’s recent financial performance, which has been disappointing.

Glaxo’s post-tax profits plunged from £5.436bn in 2013 to just £2.756bn in 2014 as the impact of patent losses on key products affected sales.

However, the situation does seem to be improving. Glaxo has now completed a major asset swap with Novartis and last week announced a new deal to acquire additional HIV products. Analysts expect full-year profits to rise by 34% to £3.691bn this year, and by a further 11% to £4.099bn in 2016.

The firm has managed to avoid cutting its dividend so far and currently offers a prospective yield of 6.1% for 2016. Big long-term backers of GlaxoSmithKline, such as star fund manager Neil Woodford, have been buying more shares this year.

Mr Woodford’s view is that short-term headwinds are overshadowing the much greater long-term earning power of Glaxo’s portfolio. This is a view I share.

For investors looking for long-term income and growth, I think that now could prove to be a good time to buy GlaxoSmithKline.

Lloyds: Stock overhang

I believe that Lloyds investors are suffering from a problem that more commonly affects shareholders in small cap companies – a stock overhang.

The overhang comes in the form of the government, which is gradually pumping its Lloyds shares back into the market. Since the end of May, the Treasury has sold 9% of Lloyds shares. That’s equivalent to £5.2bn worth of shares at today’s price.

This means that big institutional buyers of the stock have been guaranteed a good supply of Lloyds shares, without pushing up the price.

However, the share sale has been paused recently as Lloyds shares have been selling below 73.6p. This is the price at which the government bailed out Lloyds in 2008. The bankers handling the sale have been told only to sell Lloyds stock when the price is above this level.

I suspect that this requirement means Lloyds’ share price will find support at around 70p, as the volume of shares available for institutions to buy is much lower now that the government isn’t selling.

However, I also suspect that Lloyds shares won’t rise much above 73.6p until the government has sold all of its shares, which it hopes to do in 2016.

That’s why I believe now could be a good time to buy. At today’s price of 72p, Lloyds offers a prospective yield of 5.1% for 2016, and a modest forecast P/E of 9.5. The shares are supported by a book value of 68p and by 55p per share of tangible assets.

In my view Lloyds currently offers more upside potential than downside risk, and could prove a profitable buy for 2016.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of British bank notes
Investing Articles

£9,000 in savings? Here’s how to try and turn that into a £193 monthly second income

With a long-term approach and applying basic principles of good investment, our writer reckons someone with under £10k could earn…

Read more »

Investing Articles

A 2026 stock market crash could be a rare passive income opportunity

If a stock market crash comes our way then it might throw up plentiful opportunities for investors to secure a…

Read more »

Tesla car at super charger station
Investing Articles

£10,000 invested in Tesla stock 1 year ago is now worth…

Dr James Fox takes a closer look at Tesla stock with the incredibly volatile mega-cap company surging and pulling back…

Read more »

British pound data
Investing Articles

My personal warning for anyone tempted by the plunging Aston Martin share price

Harvey Jones was so captivated by the plunging Aston Martin share price that he ignored an old piece of investment…

Read more »

Stacks of coins
Investing Articles

This penny share just crashed 13% to 19p! Time to buy?

After another fall today, this penny stock has now crashed 70% since April 2021. Is it one that should be…

Read more »

Trader on video call from his home office
Investing Articles

Down 19%! Here’s why Barclays shares look a serious bargain to me right now

Barclays shares have slumped recently, but a big gap between price and fair value has opened, offering nimble long-term investors…

Read more »

CEO Mark Zuckerberg at F8 2019 event
Investing Articles

Why Meta Platforms shares fell 12.5% in March

Historically, investors have done well by buying Meta Platforms shares when the price has fallen. But is the latest legal…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

£20,000 invested in BAE Systems shares 4 years ago is now worth…

BAE Systems' shares have soared since 2022, yet rising NATO budgets are just starting to feed through, so the real…

Read more »